X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare FDC LTD. with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FDC LTD. vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FDC LTD. GLENMARK PHARMA FDC LTD./
GLENMARK PHARMA
 
P/E (TTM) x 29.1 12.2 238.1% View Chart
P/BV x 6.1 3.2 187.9% View Chart
Dividend Yield % 0.8 0.4 208.6%  

Financials

 FDC LTD.   GLENMARK PHARMA
EQUITY SHARE DATA
    FDC LTD.
Mar-14
GLENMARK PHARMA
Mar-17
FDC LTD./
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs144993 14.5%   
Low Rs79729 10.8%   
Sales per share (Unadj.) Rs47.6325.5 14.6%  
Earnings per share (Unadj.) Rs7.639.3 19.4%  
Cash flow per share (Unadj.) Rs9.048.7 18.5%  
Dividends per share (Unadj.) Rs2.252.00 112.5%  
Dividend yield (eoy) %2.00.2 870.8%  
Book value per share (Unadj.) Rs47.5159.2 29.9%  
Shares outstanding (eoy) m177.83282.17 63.0%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x2.32.6 88.4%   
Avg P/E ratio x14.621.9 66.7%  
P/CF ratio (eoy) x12.317.7 69.8%  
Price / Book Value ratio x2.35.4 43.3%  
Dividend payout %29.65.1 580.9%   
Avg Mkt Cap Rs m19,784242,991 8.1%   
No. of employees `000NA13.0 0.0%   
Total wages/salary Rs m1,22116,408 7.4%   
Avg. sales/employee Rs ThNM7,083.9-  
Avg. wages/employee Rs ThNM1,265.4-  
Avg. net profit/employee Rs ThNM855.1-  
INCOME DATA
Net Sales Rs m8,45991,857 9.2%  
Other income Rs m394374 105.3%   
Total revenues Rs m8,85292,230 9.6%   
Gross profit Rs m2,07020,367 10.2%  
Depreciation Rs m2492,644 9.4%   
Interest Rs m312,373 1.3%   
Profit before tax Rs m2,18415,724 13.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2250-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m6063,827 15.8%   
Profit after tax Rs m1,35311,088 12.2%  
Gross profit margin %24.522.2 110.4%  
Effective tax rate %27.724.3 113.9%   
Net profit margin %16.012.1 132.5%  
BALANCE SHEET DATA
Current assets Rs m4,35568,746 6.3%   
Current liabilities Rs m1,79227,027 6.6%   
Net working cap to sales %30.345.4 66.7%  
Current ratio x2.42.5 95.6%  
Inventory Days Days4485 52.3%  
Debtors Days Days2596 25.8%  
Net fixed assets Rs m3,02524,132 12.5%   
Share capital Rs m179282 63.3%   
"Free" reserves Rs m8,24344,643 18.5%   
Net worth Rs m8,45344,925 18.8%   
Long term debt Rs m1145,363 0.0%   
Total assets Rs m10,557117,639 9.0%  
Interest coverage x71.47.6 936.5%   
Debt to equity ratio x01.0 0.1%  
Sales to assets ratio x0.80.8 102.6%   
Return on assets %13.111.4 114.6%  
Return on equity %16.024.7 64.9%  
Return on capital %23.519.1 122.8%  
Exports to sales %13.30-   
Imports to sales %3.30-   
Exports (fob) Rs m1,126NA-   
Imports (cif) Rs m283NA-   
Fx inflow Rs m1,14656,152 2.0%   
Fx outflow Rs m3558,084 4.4%   
Net fx Rs m79148,068 1.6%   
CASH FLOW
From Operations Rs m1,4856,574 22.6%  
From Investments Rs m-620-7,124 8.7%  
From Financial Activity Rs m-7535,432 -13.9%  
Net Cashflow Rs m1131,992 5.7%  

Share Holding

Indian Promoters % 68.9 48.3 142.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.7 6.9 68.1%  
FIIs % 7.5 34.4 21.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.0 10.5 181.0%  
Shareholders   23,730 56,727 41.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FDC LTD. With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  ORCHID PHARMA LTD  PFIZER  

Compare FDC LTD. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FDC LTD. SHARE PRICE


Feb 23, 2018 (Close)

TRACK FDC LTD.

  • Track your investment in FDC LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FDC LTD. 8-QTR ANALYSIS

COMPARE FDC LTD. WITH

MARKET STATS